Adagene and Third Arc Bio Forge Licensing Agreement for Cancer Therapy Development

Tip Ranks
2025.11.13 12:34
portai
I'm PortAI, I can summarize articles.

Adagene Inc. announced a licensing agreement with Third Arc Bio to use its SAFEbody technology for developing cancer therapies. Third Arc Bio gains worldwide rights to research, develop, and commercialize two masked CD3 T cell engagers. Adagene receives a $5 million upfront payment and potential milestone payments up to $840 million. This collaboration aims to enhance Adagene's industry position by expanding its technology's application. Despite this, Adagene's stock is rated as a Sell due to poor financial performance and a bearish trend.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

An update from Adagene ( (ADAG) ) is now available.

On November 13, 2025, Adagene Inc. announced a licensing agreement with Third Arc Bio, allowing the latter to use Adagene’s SAFEbody technology to develop two masked CD3 T cell engagers. This agreement grants Third Arc Bio worldwide rights to research, develop, and commercialize these molecules, while Adagene receives an upfront payment of $5 million and potential milestone payments up to $840 million. The collaboration is expected to enhance Adagene’s industry positioning by expanding the application of its SAFEbody technology, potentially leading to innovative cancer therapies with improved safety profiles.

The most recent analyst rating on (ADAG) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on Adagene stock, see the ADAG Stock Forecast page.

Spark’s Take on ADAG Stock

According to Spark, TipRanks’ AI Analyst, ADAG is a Underperform.

Adagene’s overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues and significant losses. Technical analysis indicates a bearish trend, and valuation metrics highlight concerns with a negative P/E ratio. The absence of earnings call data and corporate events limits additional insights.

To see Spark’s full report on ADAG stock, click here.

More about Adagene

Adagene Inc. is a clinical-stage biotechnology company focused on developing novel antibody-based cancer immunotherapies. Utilizing its proprietary Dynamic Precision Library platform, Adagene combines computational biology and artificial intelligence to design antibodies that address unmet global patient needs. The company’s SAFEbody technology is designed to improve the safety and efficacy of antibody therapeutics by enabling tumor-specific targeting, minimizing off-target effects.

Average Trading Volume: 97,784

Technical Sentiment Signal: Strong Sell

Current Market Cap: $83.42M

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.